[Erythropoietin treatment of dialysis patients].
The effect of recombinant human erythropoietin therapy on correction of renal anaemia was evaluated. A total of 100 patients with endstage renal disease and anaemia (level of haemoglobin < 9.6 g/dl) received erythropoietin for 125 patient years. In 81 patients the level of haemoglobin increased to the intended range (10.5-12.0 g/dl) within three to four months. In 16 of the patients acute infections were followed by a temporary reduction in the haemoglobin level. In 11 patients a previous transfusion requirement was reduced, or, in most cases, abolished. In the remaining eight patients the transfusion requirement was unchanged. The patients with either a sub-optimal or no response suffered from chronic infections, malignant diseases or recurrent bleeding episodes. In 28 patients the level of haemoglobin exceeded the intended target for a period of four months (average). Serious side effects were not observed. Six patients had 'flu-like symptoms after the first injections. Three cases of thrombosis of the arterio-venous fistula were observed in two patients. The frequency of thrombosis of the vascular access did not exceed what we expected to find.
Nefrologisk afdeling, Hvidovre Hospital, København.
D I
DI
Stenver
B
B
Nielsen
D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D006435:Renal Dialysis / Q000009:adverse effects; D012189:Retrospective Studies
D004921:Erythropoietin
Erytropoietinbehandling af dialysepatienter.